2024
Postprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes
Patton S, Bergford S, Sherr J, Gal R, Calhoun P, Clements M, Riddell M, Martin C. Postprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes. Nutrients 2024, 16: 162. PMID: 38201991, PMCID: PMC10781146, DOI: 10.3390/nu16010162.Peer-Reviewed Original ResearchConceptsGlycemic variabilityGlucose variabilityType 1Continuous glucose monitoringPediatric studiesCarbohydrate intakeDay observation periodMacronutrient intakeDietary guidelinesPhysical activityExercise intensityT1DGlucose monitoringObservation periodTypical mealMeal contentMealIntakeCoefficient of variationAssociationMacronutrient contentMore carbohydratesCliniciansLarge sample
2023
Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes
Criego A, Carlson A, Brown S, Forlenza G, Bode B, Levy C, Hansen D, Hirsch I, Bergenstal R, Sherr J, Mehta S, Laffel L, Shah V, Bhargava A, Weinstock R, MacLeish S, DeSalvo D, Jones T, Aleppo G, Buckingham B, Ly T, Group F. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2023, 26: 11-23. PMID: 37850941, PMCID: PMC10794844, DOI: 10.1089/dia.2023.0364.Peer-Reviewed Original ResearchConceptsAdolescents/adultsPivotal trialsInsulin delivery systemsSingle-arm multicenter trialYears of useClinical trial registrationType 1 diabetesLong-term safetyMonths of useLong-term useDiabetic ketoacidosisMulticenter trialSevere hypoglycemiaTRIAL REGISTRATIONGlycemic outcomesType 1Delivery systemExtension phaseMonthsTrialsTarget rangeAdultsHbA1cChildrenEpisodesThe Acute Effects of Real-World Physical Activity on Glycemia in Adolescents With Type 1 Diabetes: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study.
Riddell M, Gal R, Bergford S, Patton S, Clements M, Calhoun P, Beaulieu L, Sherr J. The Acute Effects of Real-World Physical Activity on Glycemia in Adolescents With Type 1 Diabetes: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study. Diabetes Care 2023, 47: 132-139. PMID: 37922335, DOI: 10.2337/dc23-1548.Peer-Reviewed Original ResearchConceptsReal-world physical activityPhysical activityType 1Pediatric studiesHeart rateLower baseline HbA1c levelsReal-world observational studySelf-reported physical activityBaseline HbA1c levelsShorter disease durationPeak heart rateType 1 diabetesSelf-management strategiesDisease durationHbA1c levelsMedian durationLess hypoglycemiaLower BMIAcute effectsContinuous glucose monitoring dataObservational studyFood intakeEvent-level factorsInsulin dosingActive adolescentsContinuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up Results
Miller K, Bauza C, Kanapka L, Clements M, DeSalvo D, Hood K, Messer L, Sherr J, Bergamo K, Criego A, Freiner E, Lyons S, Monzavi R, Moore W, Prahalad P, Simmons J, Sulik M, Wadwa R, Weinstock R, Willi S, Williams K, Laffel L. Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up Results. Pediatric Diabetes 2023, 2023: 1-12. DOI: 10.1155/2023/6718115.Peer-Reviewed Original ResearchType 1 diabetesMedian percent timeUse of CGMBlood glucose monitoringYoung adultsCGM initiationExtension phaseGlucose monitoringPercent timeContinuous glucose monitoringMean hemoglobinGlycemic controlCGM groupUp ResultsClinical trialsGlycemic outcomesGlycemic benefitsCGM useMonitoring interventionsType 1Further evaluationBGM groupWeeksDlAdultsSafety and Glycemic Outcomes During the MiniMedTM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes
Pihoker C, Shulman D, Forlenza G, Kaiserman K, Sherr J, Thrasher J, Buckingham B, Kipnes M, Bode B, Carlson A, Lee S, Latif K, Liljenquist D, Slover R, Dai Z, Niu F, Shin J, Jonkers R, Roy A, Grosman B, Vella M, Cordero T, McVean J, Rhinehart A, Vigersky R, Bode B, Buckingham B, Carlson A, Casaubon L, Christiansen M, Cordero T, Garg S, Grosman B, Kaiserman K, Kipnes M, Latif K, Lee S, Liljenquist D, Lintereur L, Liu M, McVean J, Parikh N, Peng F, Pihoker C, Philis-Tsimikas A, Pop-Busui R, Reed J, Rhinehart A, Roy A, Sherr J, Shin J, Shulman D, Singh K, Slover R, Thrasher J, Vella M, Vigersky R, Wu D. Safety and Glycemic Outcomes During the MiniMedTM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics 2023, 25: 755-764. PMID: 37782145, DOI: 10.1089/dia.2023.0255.Peer-Reviewed Original ResearchConceptsDiabetic ketoacidosisSensor glucosePivotal trialsSevere hypoglycemiaPredictive low glucose managementSingle-arm studySensor-augmented pumpType 1 diabetesEnd of studyMean sensor glucoseEffectiveness endpointTreat populationGlycemic targetsGlucose targetsInvestigational centersPrimary safetyGlycemic outcomesMean TIRA1CType 1Higher TIRStudy periodClosed-loop useCoefficient of variationLower TBRUtility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review
Jacobsen L, Sherr J, Considine E, Chen A, Peeling S, Hulsmans M, Charleer S, Urazbayeva M, Tosur M, Alamarie S, Redondo M, Hood K, Gottlieb P, Gillard P, Wong J, Hirsch I, Pratley R, Laffel L, Mathieu C. Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review. Communications Medicine 2023, 3: 132. PMID: 37794113, PMCID: PMC10550996, DOI: 10.1038/s43856-023-00358-x.Peer-Reviewed Original ResearchType 1 diabetesTreatment of peopleSystematic reviewAdvanced hybrid closed-loop systemBaseline glycemic levelsSelf-care burdenOptimization of outcomesContinuous glucose monitoring systemHybrid closed-loop systemAdvanced complicationsStandard careGlucose monitoring systemHypoglycemia riskGlycemic levelsGlycemic variabilityDiabetes therapyDiabetesHealthcare teamInsulin pumpType 1Glucose monitoringInsulin deliveryDevice initiationBehavioral modificationFurther studies336-OR: Insulin Delivery Modality Does Not Impact Glycemic Change during Physical Activity in Youth with Type 1 Diabetes (T1D)—Results from the Real-World T1DEXI Pediatric Study
RIDDELL M, BERGFORD S, GAL R, PATTON S, CLEMENTS M, CALHOUN P, SHERR J. 336-OR: Insulin Delivery Modality Does Not Impact Glycemic Change during Physical Activity in Youth with Type 1 Diabetes (T1D)—Results from the Real-World T1DEXI Pediatric Study. Diabetes 2023, 72 DOI: 10.2337/db23-336-or.Peer-Reviewed Original ResearchInsulin delivery modalitiesPre-exercise glucoseJuvenile Diabetes Research FoundationPediatric studiesGlucose levelsDelivery modalitiesSpeakers bureauType 1 diabetesBlood glucose levelsInsulin delivery methodsNIH National InstituteAdvisory PanelGlycemic changesContinuous glucose monitorHarry B. Helmsley Charitable TrustPhysical activityExercise typeType 1Activity monitorDiabetesNovo NordiskEli LillyLeona M.Helmsley Charitable TrustT1D.575-P: Do Overnight Dips Exist following Afternoon Exercise? Factors Associated with Nocturnal Hypoglycemia in the Type 1 Diabetes Exercise Initiative Pediatric (T1DexiP) Study
SHERR J, BERGFORD S, PATTON S, CLEMENTS M, CALHOUN P, GAL R, RIDDELL M. 575-P: Do Overnight Dips Exist following Afternoon Exercise? Factors Associated with Nocturnal Hypoglycemia in the Type 1 Diabetes Exercise Initiative Pediatric (T1DexiP) Study. Diabetes 2023, 72 DOI: 10.2337/db23-575-p.Peer-Reviewed Original ResearchAfternoon exerciseJuvenile Diabetes Research FoundationNocturnal hypoglycemiaAid useSpeakers bureauMeasures logistic regressionMin/dayNIH National InstituteBedtime glucoseMedian TBRNocturnal glycemiaAdvisory PanelHypoglycemia riskContinuous glucose monitorExercise sessionsHarry B. Helmsley Charitable TrustGlucose levelsHeart rateLower riskType 1Activity monitorLogistic regressionBiphasic patternInsulin deliveryNovo Nordisk
2022
Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial
Sherr JL, Bode BW, Forlenza GP, Laffel LM, Schoelwer MJ, Buckingham BA, Criego AB, DeSalvo DJ, MacLeish SA, Hansen DW, Ly TT, Sherr J, Weyman K, Tichy E, VanName M, Brei M, Zgorski M, Steffen A, Carria L, Bode B, Busby A, Forlenza G, Wadwa R, Slover R, Cobry E, Messer L, Laffel L, Isganaitis E, Ambler-Osborn L, Freiner E, Turcotte C, Volkening L, Schoelwer M, Brown S, Krauthause K, Emory E, Oliveri M, Buckingham B, Ekhlaspour L, Kingman R, Criego A, Schwartz B, Gandrud L, Grieme A, Hyatt J, DeSalvo D, McKay S, DeLaO K, Villegas C, MacLeish S, Wood J, Kaminski B, Casey T, Campbell W, Behm K, Adams R, Hansen D, Stone S, Bzdick S, Bulger J, Agostini L, Doolittle S, Kivilaid K, Kleve K, Ly T, Dumais B, Vienneau T, Huyett L, Lee J, O’Connor J, Benjamin E. Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Diabetes Care 2022, 45: 1907-1910. PMID: 35678724, PMCID: PMC9346983, DOI: 10.2337/dc21-2359.Peer-Reviewed Original ResearchConceptsInsulin delivery systemsSingle-arm studyLong-term complicationsMulticenter clinical trialType 1 diabetesSensor glucose levelsYoung childrenBaseline data collectionReduced hypoglycemiaDiabetic ketoacidosisGlycemic targetsUsual therapyGlycemic measuresSevere hypoglycemiaDelivery systemStudy endGlycemic outcomesClinical trialsGlucose levelsType 1HypoglycemiaInvestigational systemDlChildrenStudy phase
2021
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes
Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, Lilenquist DR, Brazg RL, Kaiserman KB, Kipnes MS, Thrasher JR, Reed JHC, Slover RH, Philis-Tsimikas A, Christiansen M, Grosman B, Roy A, Vella M, Jonkers RAM, Chen X, Shin J, Cordero TL, Lee SW, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2021, 24: 178-189. PMID: 34694909, PMCID: PMC8971997, DOI: 10.1089/dia.2021.0319.Peer-Reviewed Original ResearchConceptsAdvanced hybrid closed-loop systemMulticenter single-arm studyPredictive low glucose managementDiabetic ketoacidosis eventsSingle-arm studySensor-augmented pumpType 1 diabetesWilcoxon signed-rank testStudy phaseKetoacidosis eventsTreat populationHybrid closed-loop systemMean A1CGlycemic targetsGlucose targetsPivotal trialsStudy endpointGlucose managementGlycemic outcomesSigned-rank testAge groupsStudy participantsType 1Safety eventsA1CReal-World, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes Using the MiniMed 670G Hybrid Closed-Loop System
DuBose SN, Bauza C, Verdejo A, Beck RW, Bergenstal RM, Sherr J, Levy C, Levister C, Lam D, O'Malley G, Ogyaadu S, Lovett J, Abram V, Kudva Y, McCrady Spitzer S, Reid C, Kumari K, Dadlani V, Goland R, Pollak S, Alvarez A, Zagoren E, Deliard J, Kruger D, Hunter H, Smith A, Remtema H, Hiers P, Albanese-O'Neill A, Haller M, Adams J, Greco M, Peters A, Harmel M, Weinstock R, Bzdick S, Bulger J, Agonstini L, Conboy P, Doolittle S, Aleppo G, Bansal A, Thompson M, Arsiniega E, Hubacz L, Monzavi R, Raymond J, Brimberry D, Torres Sanchez A, Simmons J, Rainer K, Brendle F, Williams G, Kelley J, Clements M, McDonough R, Watkins D, Elrod A, Seuferling B, Harding H, James J, Orlich S, Raman V, Foster C, Davis C, Slater H, Ocanovic Z, Kingery S, Wintergerst K, Watson S, Eubanks S, Pierce G, Rush H, Wong J, Dapkus L, Wood J, Adams R, Blomquist G, Sterchi L, Welch S, Gouine D, Racki S, Hodax J, Beauregard N, Pascual C, Franklin C, Bethin K, Majumdar I, Mastrandrea L, Quattrin T, Tabaczynski E, House A. Real-World, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes Using the MiniMed 670G Hybrid Closed-Loop System. Diabetes Technology & Therapeutics 2021, 23: 791-798. PMID: 34524023, DOI: 10.1089/dia.2021.0176.Peer-Reviewed Original ResearchConceptsHybrid closed-loop systemHybrid closed-loop insulin delivery systemMean percent timeRoutine clinical visitsPatient-reported outcomesType 1 diabetesClosed-loop insulin delivery systemUsual careClinical outcomesClinical visitsInsulin delivery systemsSleep interruptionClinical dataClinic dataType 1Glucose monitor dataPercent timeMonthsTarget rangePatientsContinuous glucose monitor dataAdequate trainingBaselineCurrent knowledgeOutcomesHemoglobin A1c Patterns of Youth With Type 1 Diabetes 10 Years Post Diagnosis From 3 Continents
Sherr JL, Schwandt A, Phelan H, Clements MA, Holl RW, Benitez-Aguirre PZ, Miller KM, Woelfle J, Dover T, Maahs DM, Fröhlich-Reiterer E, Craig ME. Hemoglobin A1c Patterns of Youth With Type 1 Diabetes 10 Years Post Diagnosis From 3 Continents. Pediatrics 2021, 148: e2020048942. PMID: 34315809, PMCID: PMC8785705, DOI: 10.1542/peds.2020-048942.Peer-Reviewed Original ResearchType 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation
Perkins BA, Sherr JL, Mathieu C. Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation. Science 2021, 373: 522-527. PMID: 34326234, DOI: 10.1126/science.abg4502.Peer-Reviewed Original ResearchConceptsInsulin therapySelf-care burdenSufficient glycemic controlType 1 diabetesRapid insulin analoguesInsulin delivery methodsInsulin delivery routeBroad clinical implementationMost patientsGlycemic controlGlycemic managementPharmacological advancesInsulin analoguesPharmacological solutionsInsulin pumpActivity monitorType 1Weight gainInsulin effectGlucose monitoringTherapyClinical implementationDelivery methodsInsulin moleculeKey metabolitesMulticenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes
Brown SA, Forlenza GP, Bode BW, Pinsker JE, Levy CJ, Criego AB, Hansen DW, Hirsch IB, Carlson AL, Bergenstal RM, Sherr JL, Mehta SN, Laffel LM, Shah VN, Bhargava A, Weinstock RS, MacLeish SA, DeSalvo DJ, Jones TC, Aleppo G, Buckingham BA, Ly TT, Brown S, Voelmle M, Emory E, Forlenza G, Wadwa R, Slover R, Cobry E, Messer L, Berget C, McCoy S, Shah V, Akturk H, Schneider N, Joseph H, Joshee P, Beatson C, Bode B, Narron B, Lopez T, Pinsker J, Church M, Castorino K, Piper M, Perez J, Levy C, Lam D, Levister C, O’Malley G, Ogyaadu S, Arasaratnam D, Plesser M, Nosova E, Bzdick S, Hansen D, Stone S, Weinstock R, Hirsch I, Trikudanathan S, Sanborn N, Khakpour D, Carlson A, Criego A, Bergenstal R, Martens T, Grieme A, Hyatt J, Punel A, Whipple D, Sherr J, Van Name M, Brei M, Zgorski M, Steffen A, Carria L, Mehta S, Laffel L, Roethke L, Fisher M, La Banca R, Volkening L, Ambler-Osborn L, Turcotte C, Freiner E, Bhargava A, Borg L, MacLeish S, Wood J, Kaminski B, Casey T, Campbell W, DeSalvo D, McKay S, DeLaO M, Villegas C, Jones T, Johns B, Gore A, Harvill L, Merritt K, Stanfield J, Sheldon J, Hichkad L, Burnett E, Castelot A, Bounds L, Preston K, Goldfaden R, Aleppo G, Kravarusic J, Bansal A, Buckingham B, Ekhlaspour L, Kingman R, Kivilaid K, Kleve K, Ly T, Dumais B, Vienneau T, Huyett L, Lee J, O’Connor J, Benjamin E. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care 2021, 44: 1630-1640. PMID: 34099518, PMCID: PMC8323171, DOI: 10.2337/dc21-0172.Peer-Reviewed Original ResearchConceptsInsulin delivery systemsGlycemic targetsDiabetic ketoacidosis eventsPrimary safety outcomePrimary effectiveness outcomeSevere hypoglycemia eventsTarget glucose rangeBurden of diseaseType 1 diabetesPivotal safety studiesKetoacidosis eventsDiabetic ketoacidosisStandard therapyMulticenter trialSevere hypoglycemiaDelivery systemProspective studyHypoglycemia eventsTreatment paradigmAutomated Insulin Delivery SystemsSafety outcomesEffectiveness outcomesTherapy phaseSensor glucoseType 1Adjunctive Therapies for Type 1 Diabetes
Nally L, Van Name M, Tamborlane W, Sherr J. Adjunctive Therapies for Type 1 Diabetes. Contemporary Endocrinology 2021, 143-150. DOI: 10.1007/978-3-030-64133-7_13.Chapters
2020
A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention
Nally LM, Wagner J, Sherr J, Tichy E, Weyman K, Ginley MK, Zajac K, Desousa M, Shabanova V, Petry NM, Tamborlane WV, Van Name M. A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention. Endocrine Practice 2020, 27: 545-551. PMID: 34120699, PMCID: PMC8206518, DOI: 10.1016/j.eprac.2020.11.017.Peer-Reviewed Original ResearchChanges in Device Uptake and Glycemic Control Among Pregnant Women With Type 1 Diabetes: Data From the T1D Exchange
Levy CJ, Foster NC, DuBose SN, Agarwal S, Lyons SK, Peters AL, Uwaifo GI, DiMeglio LA, Sherr JL, Polsky S. Changes in Device Uptake and Glycemic Control Among Pregnant Women With Type 1 Diabetes: Data From the T1D Exchange. Journal Of Diabetes Science And Technology 2020, 15: 1297-1302. PMID: 33218278, PMCID: PMC8655289, DOI: 10.1177/1932296820972123.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionPregnant womenEligible participantsCohort 2Continuous glucose monitorGlycemic outcomesT1D Exchange Clinic RegistryDevice useSubcutaneous insulin infusionHemoglobin A1c resultsT1D pregnancyGlycemic controlClinic registryT1D ExchangeCSII useA1C resultsInsulin infusionMedical recordsCohort 1CGM useType 1Device uptakeWomenSurvey completionAdditional evaluation
2019
Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
Sherr J, Buckingham BA, Forlenza G, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett L, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology & Therapeutics 2019, 22: 174-184. PMID: 31596130, PMCID: PMC7047109, DOI: 10.1089/dia.2019.0286.Peer-Reviewed Original ResearchConceptsDaily physical activityPhysical activityFree-living conditionsPercentage timeMultiple daily injectionsType 1 diabetesRespective age groupsCohort of participantsHybrid closed-loop systemPrimary endpointDaily injectionsEligible participantsClosed-loop studiesPercentage of timeTherapy phaseInvestigational deviceNights of useAge groupsSensor glucoseType 1Home settingDlSignificant decreaseUsual routineAdults215-OR: Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes
BUCKINGHAM B, FORLENZA G, SHERR J, GALDERISI A, EKHLASPOUR L, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. 215-OR: Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes. Diabetes 2019, 68 DOI: 10.2337/db19-215-or.Peer-Reviewed Original ResearchDiabetes careMedtronic MiniMedSevere hypoglycemic eventsChildren Aged 2Advisory PanelYoung childrenMin/dAge 4.2Oral carbohydrateHybrid closed-loop systemHypoglycemic eventsGlycemic outcomesMean glucoseAged 2CGM useTherapy phaseInvestigational deviceType 1T1D therapyPercent timeMiniMedLexicon PharmaceuticalsCareUsual routineAdult participants
2018
157 Nasal Glucagon: Potentially Viable Alternative to Treat Insulin-Induced Hypoglycemia in Adults with Type 1 Diabetes
Suico J, Hövelmann U, Zhang S, Shen T, Bergman B, Sherr J, Zijlstra E, Frier B, Plum-Morschel L. 157 Nasal Glucagon: Potentially Viable Alternative to Treat Insulin-Induced Hypoglycemia in Adults with Type 1 Diabetes. Canadian Journal Of Diabetes 2018, 42: s53. DOI: 10.1016/j.jcjd.2018.08.162.Peer-Reviewed Original Research